Evidence map›Paper›PMID 31754890›Full record

ReviewCurrent rheumatology reports2019

PET Scan: Nuclear Medicine Imaging in Myositis.

Albert Selva-O'Callaghan, Albert Gil-Vila, Marc Simó-Perdigó, Ernesto Trallero-Araguás, Marcelo Alvarado-Cárdenas, Iago Pinal-Fernandez

Open access · greenAbstract readReview
In one paragraph

Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. American journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
  4. Treatment and Monitoring of Eosinophilic Fasciitis.Current treatment options in rheumatology · 2025
    Article
  5. Imaging in myositis: MRI orClinical rheumatology · 2022
    Article
  6. Observational
  7. Article
  8. Clinical Value ofFrontiers in immunology · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Albert Selva-O'CallaghanInternal Medicine Department, Vall d'Hebron General Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain. aselva@vhebron.net.
Albert Gil-VilaInternal Medicine Department, Vall d'Hebron General Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Marc Simó-PerdigóNuclear Medicine Department, Vall d'Hebron General Hospital, Barcelona, Spain.
Ernesto Trallero-AraguásRheumatology Unit, Vall D'Hebron General Hospital, , Barcelona, Spain.
Marcelo Alvarado-CárdenasInternal Medicine Department, Vall d'Hebron General Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Iago Pinal-FernandezNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Johns Hopkins University School of Medicine, Baltimore, USA.
Universitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ESNational Institute of Arthritis and Musculoskeletal and Skin Diseases · US

Funding

Intramural NIH HHS Z99 AR999999
6 · The paper itself

Abstract

purpose of reviewPositron emission tomography (PET) combined with computed tomography (CT) has proven useful as a cancer screening technique in patients with inflammatory myopathy, mainly dermatomyositis. In this review, we focus on advances in this direction and other potential applications of PET/CT in patients with inflammatory myopathy. RECENT

findingsCancer screening by PET/CT seems suitable and cost-effective in patients with myositis. It has also shown value as a hybrid technique for diagnosing myositis versus controls and could be of interest for differentiating between polymyositis and sporadic inclusion body myositis. Quantification of muscle activity by PET/CT seems reliable. Preliminary data suggest that it could also be used to diagnose and measure the activity of the disease in the lung. PET/CT should be in the toolbox of physicians managing patients with myositis. The multiple applications of PET/CT include its value for cancer screening, measuring the activity of the disease in muscle, and helping to differentiate between myositis phenotypes. The possibility to diagnose and monitor inflammatory lung activity remains to be demonstrated in well-designed studies.

Indexed as

DermatomyositisDiagnosis, DifferentialHumansMass ScreeningMyositisNeoplasmsPolymyositisPositron Emission Tomography Computed TomographyActivityDermatomyositisMalignancyMyositisPET/CTSporadic inclusion body myositis

Identifiers

PMID31754890
PMCPMC11611048
OpenAlexW2989892058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.